

News Release

News Release

CONTACT: Andrew Bright
+ 1 (484) 530 3922
andrew.bright@oncura.com
www.oncura.com

ONCURA™ Expands its Product Line with RAPID Strand™ Rx.

San Francisco (June 1, 2005) – ONCURA, a global leader in the minimally invasive management of prostate cancer is committed to the development of innovative products that improve outcomes in patients treated with prostate brachytherapy. During the 2005 meeting of the American Brachytherapy Society (ABS) ONCURA announced the introduction of RAPID Strand Rx, a pre-loaded, variable per patient prescription version of its unique prostate brachytherapy product RAPID Strand.

"Our 2000 publication comparing the use of RAPID Strand with loose seeds clearly shows RAPID Strand to be associated with improved delivery of treatment," said W. Robert Lee MD, M.S. Professor and Vice Chairman of Radiation Oncology at Wake Forest University, NC. He added, "RAPID Strand Rx will increase convenience for the whole team involved in ordering and preparing for prostate brachytherapy cases, and will allow more patients to benefit from the proven benefits of RAPID Strand's unique design."

The introduction of RAPID Strand Rx will increase patient access by making proven long term clinical benefits more widely available, while increasing convenience to brachytherapy programs. RAPID Strand contributed to the initial growth of prostate brachytherapy during the 1990's and through peer reviewed evaluation and publication has demonstrated its clinical value. The launch of a pre-loaded version of RAPID Strand that can be tailored to each patient will allow the assurance of long term clinical data to be offered to an even wider range of patients.

"Our commitment to the continued development of prostate brachytherapy is exemplified by the launch of RAPID Strand Rx," said James McGlone, CEO and President of ONCURA. He added, "Having pioneered the development of RAPID Strand and seen the positive impact it's had on patient outcomes, our belief in continued innovation to address patient and physician needs has led us to the introduction of this new option."

ONCURA was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.